Download PDF
TumorDiagnostik & Therapie 2020; 41(04): 240-245
DOI: 10.1055/a-1103-8770
Schwerpunkt Hämatologische Tumoren

Neue Therapien für Patienten mit Non-Hodgkin-Lymphomen

Erik Gaitzsch
,
Oliver Weigert
› Further Information
Also available at
    Permissions and Reprints

Die Einführung einer Vielzahl neuer Therapeutika hat die Behandlungsmöglichkeiten von Patienten mit Non-Hodgkin-Lymphomen (NHL) erheblich erweitert. Insbesondere die Weiterentwicklung zielgerichteter Medikamente wird unsere Therapiekonzepte grundlegend verändern. Anhand von ausgewählten Beispielen gibt dieser Text einen allgemeinen Überblick über aktuelle Therapieoptionen.

Publication History

Article published online:
11 May 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Maloney DG, Grillo-Lopez AJ, Bodkin DJ. et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274
    CrossrefPubMedGoogle Scholar
  • 2 Younes A, Ansell S, Fowler N. et al. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol 2017; 14: 335-346
    CrossrefPubMedGoogle Scholar
  • 3 Karaman MW, Herrgard S, Treiber DK. et al. quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-132
    CrossrefPubMedGoogle Scholar
  • 4 Lancet JE, Uy GL, Cortes JE. et al. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 2018; 36: 2684-2692
    CrossrefPubMedGoogle Scholar
  • 5 Rodriguez MA, Durand J, Astrow A. et al. Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients older than age 60 with untreated diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2011; 29 (Suppl. 15) 8053-8053
    CrossrefPubMedGoogle Scholar
  • 6 Rummel MJ, Niederle N, Maschmeyer G. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210
    CrossrefPubMedGoogle Scholar
  • 7 Pettengell R, Coiffier B, Narayanan G. et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol 2012; 13: 696-706
    CrossrefPubMedGoogle Scholar
  • 8 Pettengell R, Dlugosz-Danecka M, Andorsky D. et al. Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). Br J Haematol 2020; 188: 240-248
    CrossrefPubMedGoogle Scholar
  • 9 Robak T, Jin J, Pylypenko H. et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol 2018; 19: 1449-1458
    CrossrefPubMedGoogle Scholar
  • 10 Ghobrial IM, Hong F, Padmanabhan S. et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28: 1422-1428
    CrossrefPubMedGoogle Scholar
  • 11 Seymour JF, Kipps TJ, Eichhorst B. et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med 2018; 378: 1107-1120
    CrossrefPubMedGoogle Scholar
  • 12 Younes A. New drugs for new targets in lymphoma. Hematol Oncol 2019; 37 (Suppl. 01) 105-109
    CrossrefPubMedGoogle Scholar
  • 13 Friedberg JW, Sharman J, Sweetenham J. et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578-2585
    CrossrefPubMedGoogle Scholar
  • 14 Bussel J, Arnold DM, Grossbard E. et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol 2018; 93: 921-930
    CrossrefPubMedGoogle Scholar
  • 15 Jain N, Keating M, Thompson P. et al. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 2019; 380: 2095-2103
    CrossrefPubMedGoogle Scholar
  • 16 Wilson WH, Young RM, Schmitz R. et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 2015; 21: 922-926
    CrossrefPubMedGoogle Scholar
  • 17 Erdmann T, Klener P, Lynch JT. et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood 2017; 130: 310-322
    CrossrefPubMedGoogle Scholar
  • 18 Dreyling M, Santoro A, Mollica L. et al. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 2017; 35: 3898-3905
    CrossrefPubMedGoogle Scholar
  • 19 Rule S, Jurczak W, Jerkeman M. et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 2018; 32: 1799-1803
    CrossrefPubMedGoogle Scholar
  • 20 Hess G. mTOR inhibition in diffuse large B-cell lymphoma: new hope?. Lancet Haematol 2016; 3: e302-e303
    PubMedGoogle Scholar
  • 21 Sermer D, Pasqualucci L, Wendel HG. et al. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol 2019; 16: 494-507
    CrossrefPubMedGoogle Scholar
  • 22 Chapuy B, Stewart C, Dunford A. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018; 24: 679-690
    CrossrefPubMedGoogle Scholar
  • 23 Pastore A, Jurinovic V, Kridel R. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol 2015; 16: 1111-1122
    CrossrefPubMedGoogle Scholar
  • 24 Schmitz R, Wright GW, Huang DW. et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med 2018; 378: 1396-1407
    CrossrefPubMedGoogle Scholar
  • 25 Beguelin W, Popovic R, Teater M. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013; 23: 677-692
    CrossrefPubMedGoogle Scholar
  • 26 Morschhauser F, Tilly H, Chaidos A. et al. Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma. Blood 2019; 134 (Suppl. 01) 123
    PubMedGoogle Scholar
  • 27 Marcus R, Seymour JF, Hiddemann W. Obinutuzumab Treatment of Follicular Lymphoma. N Engl J Med 2017; 377: 2605-2606
    CrossrefPubMedGoogle Scholar
  • 28 Sehn LH, Herrera AF, Flowers CR. et al. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol 2020; 38: 155-165
    PubMedGoogle Scholar
  • 29 Advani R, Flinn I, Popplewell L. et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. N Engl J Med 2018; 379: 1711-1721
    CrossrefPubMedGoogle Scholar
  • 30 Ansell SM, Lesokhin AM, Borrello I. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-319
    CrossrefPubMedGoogle Scholar
  • 31 Ramchandren R, Domingo-Domenech E, Rueda A. et al. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. J Clin Oncol 2019; 37: 1997-2007
    CrossrefPubMedGoogle Scholar
  • 32 Zinzani PL, Santoro A, Gritti G. et al. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. J Clin Oncol 2019; 37: 3081-3089
    CrossrefPubMedGoogle Scholar
  • 33 Rosenwald A, Wright G, Leroy K. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-862
    CrossrefPubMedGoogle Scholar
  • 34 Savage KJ, Monti S, Kutok JL. et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871-3879
    CrossrefPubMedGoogle Scholar
  • 35 Schuster SJ, Bartlett NL, Assouline S. et al. Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. Blood 2019; 134 (Suppl. 01) 6
    PubMedGoogle Scholar
  • 36 Locke FL, Ghobadi A, Jacobson CA. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol 2019; 20: 31-42
    CrossrefPubMedGoogle Scholar
  • 37 Schuster SJ, Bishop MR, Tam CS. et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019; 380: 45-56
    CrossrefPubMedGoogle Scholar
  • 38 Sehgal AR, Godwin J, Pribble J. et al. Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study. Blood 2019; 134 (Suppl. 01) 2882
    CrossrefPubMedGoogle Scholar
  • 39 Liu E, Marin D, Banerjee P. et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 2020; 382: 545-553
    CrossrefPubMedGoogle Scholar
  • 40 Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood 2015; 126: 2366-2369
    PubMedGoogle Scholar
  • 41 Kronke J, Udeshi ND, Narla A. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014; 343: 301-305
    CrossrefPubMedGoogle Scholar
  • 42 Lu G, Middleton RE, Sun H. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 2014; 343: 305-309
    CrossrefPubMedGoogle Scholar
  • 43 Morschhauser F, Fowler NH, Feugier P. et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N Engl J Med 2018; 379: 934-947
    CrossrefPubMedGoogle Scholar
  • 44 Leonard JP, Trneny M, Izutsu K. et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol 2019; 37: 1188-1199
    CrossrefPubMedGoogle Scholar